Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

Polymorphisms contribute to inter-individual differences and show a promising predictive role for chemotherapy-related toxicity in colon cancer (CC). TOSCA is a multicentre, randomized, non-inferiority, phase III study conducted in high-risk stage II/stage III CC patients treated with 6 vs 3 months...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruzzo, Annamaria, Graziano, Francesco, Galli, Francesca, Galli, Fabio, Rulli, Eliana, Lonardi, Sara, Ronzoni, Monica, Massidda, Bruno, Zagonel, Vittorina, Pella, Nicoletta, Mucciarini, Claudia, Labianca, Roberto, Ionta, Maria Teresa, Bagaloni, Irene, Veltri, Enzo, Sozzi, Pietro, Barni, Sandro, Ricci, Vincenzo, Foltran, Luisa, Nicolini, Mario, Biondi, Edoardo, Bramati, Annalisa, Turci, Daniele, Lazzarelli, Silvia, Verusio, Claudio, Bergamo, Francesca, Sobrero, Alberto, Frontini, Luciano, Magnani, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687727/
https://www.ncbi.nlm.nih.gov/pubmed/31395900
http://dx.doi.org/10.1038/s41598-019-47627-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687727/
https://www.ncbi.nlm.nih.gov/pubmed/31395900
http://dx.doi.org/10.1038/s41598-019-47627-1

Ejemplares similares